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Advances in technology are energizing the field of membrane protein structure. 
 
After decades of slow progress, the pace of research on membrane protein structures 
is beginning to quicken thanks to various improvements in technology, including protein 
engineering and micro-focus X-ray diffraction. Recent breakthroughs include structures of 
GPCR’s1-6, P-ATPases7, 8, secondary active transporters9-17, ABC transporters18, 19 and ion 
channels20.   Here we review these developments and, where possible, highlight generic new 
approaches to solving membrane protein structures based on the technological advances of 
the past few years. Rational approaches to overcoming the bottlenecks in structure 
determination are urgently required as membrane proteins, which typically comprise ~30% of 
the proteomes of organisms, are still dramatically underrepresented in the structural 
database of the Protein Data Bank. 
Electron crystallography is currently the only technique that can solve structures of 
membrane proteins in their native environment, as exemplified by the seminal structure of 
bacteriorhodopsin solved by electron diffraction using naturally occurring two-dimensional 
crystals21. But this approach is not widely used because the production of two-dimensional 
crystals that diffract to high-resolution is far from simple, with only about 8 membrane protein 
structures determined to atomic resolution, although another 30-40 structures have been 
determined at an intermediate resolution sufficient to delineate transmembrane α-helices. In 
addition, the methodology to determine structures from two-dimensional crystals has not 
been developed into user-friendly software as is the case for determining structures from X-
ray diffraction data. Therefore, the predominant technique in membrane protein structural 
projects is X-ray crystallography of three-dimensional crystals.  
To produce crystals that diffract to high resolution, sufficient amounts of the membrane 
protein are required in a form that is stable and compatible with well-ordered packing. Few 
membrane proteins are naturally abundant in their native membranes, with notable 
exceptions such as mammalian and bacterial rhodopsins, aquaporins, respiratory 
complexes, ATPases, photosynthetic complexes, reaction centers and light harvesting 
proteins. Inevitably, these proteins were among the first to have their structures solved. For 
the vast majority, however, recombinant production is the first bottleneck that must be 
tackled to secure the hundreds-of-milligram quantities necessary for a successful structural 
biology project.  
Once sufficient expression has been achieved, the next barrier is purification of the 
protein in stable form. The native membrane environment imparts considerable stability to 
membrane proteins through its lipid composition and physicochemical properties. When 
solubilized in detergents, many membrane proteins cannot be purified as they rapidly 
denature and often aggregate. This second bottleneck is particularly acute for membrane 
3 
 
proteins from higher eukaryotes, and most membrane protein structures determined to date 
are from bacteria or archaea, often focusing on homologs of mammalian proteins. These 
structures have been solved mostly using X-ray diffraction in combination with detergent 
crystallization protocols. 
Crystallization trials have benefited from major strides in automation and miniaturization 
in recent years. However, the success rate in advancing from purified protein to high-
resolution structure is still disappointingly low, and this third bottleneck is exacerbated by the 
challenges of data collection from microcrystals. Nevertheless, the rate of progress is 
accelerating, with structures of recombinant membrane proteins22 becoming increasingly 
significant within the pipeline of membrane protein structural biology (Fig. 1a). Moreover, as 
the database of membrane protein structures has grown, the use of molecular replacement 
to sidestep the time-consuming task of experimental phasing has become more common 
(Fig. 1b).    
 
Rationalizing production of recombinant membrane proteins 
Understanding the host organism better is an emerging strategy for achieving high 
yields of recombinant membrane proteins23, 24 through improvements of the host cell. In 
contrast, the conventional approach of repeated rounds of trial-and-error ’optimization’ simply 
varies external parameters (e.g., promoter and fusion tag combinations or culture process 
parameters such as pH, temperature and aeration) and cannot provide insight into the 
biology of recombinant protein production. More targeted approaches, such as deletions in 
protease or secretion pathways based on speculation about where bottlenecks lie, can be 
successful on a case-by-case basis, but also do not reveal the relevant mechanisms of a 
high-yielding cell.  
Knowledge of how membrane proteins are synthesized in the cell is still very poor. For 
example, although each host cell appears to have a number of unique accessory factors 
required for membrane protein biogenesis, their precise roles are unclear. This means that, 
although any membrane protein can in principle be produced in any system, because of 
subtle differences between signal-recognition particles, translocon components, cellular 
chaperones and foldases, the efficiency of heterologous overproduction may be very low. An 
extensive comparison of membrane proteins produced in various heterologous host 
systems25 concluded, perhaps unsurprisingly, that the best host was the one most closely 
related in evolution to the source of the target membrane protein. Hence, production of 
mammalian membrane proteins in E. coli26 usually requires considerable time and effort to 
achieve functional levels suitable for subsequent purification. Successful strategies, which 
rely on using low-copy-number plasmids, weak promoters and low temperatures during 
induction27, are thought to allow sufficient time for folding of the membrane protein while 
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keeping the amount of mRNA encoding the mammalian membrane protein to a minimum. 
This prevents the cellular ribosomes from synthesizing the heterologous protein at the 
expense of host-cell proteins and prevents accumulation of misfolded protein.  
These conditions seem to parallel the prolonged expression profiles for mammalian 
membrane proteins produced in mammalian cells. For example, the mu-opioid receptor has 
a half-time of appearance at the cell surface of 135 min, with 120 min required for the 
nascent polypeptide chain to fold and exit the endoplasmic reticulum28. The cystic fibrosis 
transmembrane conductance regulator (CFTR), an ABC transporter, shows a similarly slow 
maturation period to reach the cell surface29. In both cases, a considerable proportion of the 
nascent polypeptide chain is misfolded and degraded, so only ~40% and 25% of the mu-
opioid receptor and CFTR nascent polypeptide chains, respectively, actually make it to the 
cell surface in a functional form. Similarly, overproduction of the mu-opioid receptor in Pichia 
pastoris results in only 22% of the receptor being functional30. The role of molecular 
chaperones in this folding process is largely unexplored, although calnexin is likely to play a 
part in the folding of N-glycosylated membrane proteins, such as the serotonin transporter31, 
where it can also recruit other molecular chaperones to form a folding complex. Only a few 
attempts have been made to improve membrane protein production by co-expression of 
molecular chaperones, and they have mostly met with only a modest success, with a 2–3 
fold improvement in yields31, 32. Presumably, the levels of multiple molecular chaperones 
have to be carefully controlled before the full folding pathway can be accelerated to enhance 
significantly membrane protein overproduction.  
Understanding the protein biogenesis machinery and the physiological response of host 
cells to membrane protein production is crucial for identifying the bottlenecks in expression 
and designing strategies to improve yields. The application of ‘omics’ technologies has 
already contributed to our understanding of membrane protein production in bacteria and 
yeast and provided rationales for the forward engineering of these cells23, 24, 33. Interestingly, 
all these studies have shown that tuning the transcript levels of identified genes (either up or 
down) is crucial for successful production trials. In addition, much is to be gained from the 
optimization of the downstream steps of membrane protein biogenesis, but again finetuning 
is critical as the pathway components may otherwise heighten the production hurdle.  
One advance in this area arose from an early analysis of membrane protein production 
in Escherichia coli34. Increases in levels of chaperones and proteases were associated with 
increased membrane protein production, and it was speculated that low yields were due to 
limited Sec translocon capacity. Previously, a systems biotechnology approach to 
recombinant membrane protein production in the eukaryotic microbe Saccharomyces 
cerevisiae had identified 39 host-cell genes whose production was significantly altered when 
the aquaporin Fps1 was produced under high-yielding conditions (20°C, pH5) compared to 
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low-yielding standard growth conditions (30°C, pH5) 35. In particular, an essential gene, 
BMS1, with a role in ribosome biogenesis, was identified as always up-regulated in high-
yielding host cells23, 36. Subsequent overproduction of BMS1 in a doxycycline-titratable 
manner revealed that maximal Fps1 yield was significantly correlated with an optimum level 
of BMS1 transcript. By further titrating the overproduction of BMS1, the functional yields of a 
range of membrane proteins could be improved by a factor of up to 70. In the future it will be 
possible to apply this approach to a yeast species that has been used widely in membrane 
protein projects, given the recent publication of a curated P. pastoris genome37, as well as to 
other host cells and protein targets. 
A second advance has been in the development of alternative host-cell factories. 
Unexpectedly, the accumulation of host-cell biomass does not necessarily lead to a 
correlated increase in membrane protein yield, and in the case of G-protein-coupled 
receptors (GPCRs) produced in yeast, specific activity is often lower38. Indeed, it has been 
noted that higher cell densities can generate cellular stresses leading to modifications in 
membrane composition39, and that this modified environment influences the activity of 
recombinant proteins. Consequently, medium cell density fermentation procedures for GPCR 
production have been suggested to be preferable to those that maximize biomass yields38. In 
a recent example of host development, a respiratory S. cerevisiae strain was reported that 
has improved biomass properties, leading to increased functional yields without the need to 
resort to complex cultivation schemes40. The yield of functional human adenosine A2A 
receptor was quadrupled in this new strain compared to that from wild-type cells. 
The Gram-positive bacterium Lactococcus lactis has also been used as an alternative 
host to produce a wide range of eukaryotic and prokaryotic membrane proteins41, enabling a 
comparison of the production potential of L. lactis and E. coli42, 43. Although a large fraction of 
proteins could be produced in both hosts, some could only be produced in one or the other. 
Notably, for about half of the proteins produced in E. coli, additional bands of lower molecular 
weight were observed, indicative of breakdown products, whereas only 10% of the proteins 
produced in L. lactis were degraded. The ability to incorporate selenomethionine efficiently 
into proteins (>90%) produced in L. lactis44, 45 now greatly extends the usefulness of this 
production host for X-ray crystallography projects46.  
The establishment of green fluorescent protein (GFP) as a reporter to assess 
quantitatively the functional yields of membrane proteins has also moved the field forward47-
50. When a membrane protein that is fused N-terminally to GFP becomes misfolded during 
biosynthesis, it drags GFP into a misfolded, SDS-sensitive state. If, however, the membrane 
protein is properly folded, the GFP barrel will be synthesized as a fluorescent, SDS-resistant 
moiety; the SDS-sensitive and SDS-resistant conformations can be readily discriminated on 
SDS-PAGE and immunoblots. Thus, one can simultaneously quantify the levels of folded and 
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aggregated membrane protein. The method requires only standard equipment, small culture 
samples, is not labor-intensive and can greatly facilitate the optimization of membrane 
protein production and crystallization experiments in E. coli, L. lactis and yeast47-50. GFP 
fusions have also been widely used in pre-crystallization strategies using fluorescence-
detection size-exclusion chromatography51. Only nanogram quantities of impure protein are 
needed to evaluate the localization and yield, the degree of monodispersity, and the 
approximate molecular mass of the recombinant protein. Additionally, using a directed-
evolution approach and combining GFP-fusions with an antibiotic resistance marker, it has 
been possible to select for host strains that produce more functional membrane protein33.  
Fluorescent labeling of recombinant membrane proteins on the extracellular side of the 
cell’s plasma membrane offers an important advantage as only functional proteins correctly 
inserted into the membrane are visualized, whereas incorrectly folded proteins in the 
cytoplasm remain invisible. Post-translational labeling with small fluorescent probes such as 
fused acyl carrier protein tags can deliver novel information about the functional state of 
GPCRs both in live cells and in detergent-solublilized forms52, 53. In the case of transporters 
and ionotropic receptors, functional activity is classically assayed by measuring the transport 
of charged molecules or ions across native or reconstituted membranes. This requires the 
very time-consuming preparation of planar bilayer membranes or patch-clamp experiments. 
In a recent development, electrophysiological tests on chips have been used to substantially 
reduce the time and material required for testing function during purification of some 
membrane proteins54. 
 
Improving the stability of membrane proteins 
The stability of a membrane protein in detergent solution is crucial for producing well-
diffracting crystals55. Successful conditions have been found through extensive screens using 
rapid assays such as GFP-tagging coupled to size exclusion chromatography or dot-blotting 
techniques. Although this approach identifies the few membrane proteins naturally stable in 
detergent, it is not useful for determining the structure of particular mammalian membrane 
proteins of interest. In the last couple of years, several new approaches have been 
developed to improve the stability of membrane proteins, particularly GPCRs56. 
Among GPCRs, only rhodopsin is present in native tissues at sufficiently high levels to 
allow purification of milligrams of protein. Rhodopsin is also extremely stable in detergent, 
which has allowed structure determination of bovine rhodopsin57 and squid rhodopsin2 both 
in the dark-adapted inactive state and in an active-like state3, 6. The stability of dark-adapted 
rhodopsin is partly due to the fact that it remains in a single conformation until a photon of 
light activates its covalently bound chromophore, retinal. In contrast, hormone-binding 
GPCRs have long resisted crystallization because in detergent solution they are in 
7 
 
equilibrium between two basic conformations: one that bind G proteins (R*) and another that 
cannot (R). A mixture of multiple conformations makes crystal formation less likely. In 
addition, R* is itself often unstable, leading to rapid inactivation of all the receptor molecules 
in solution as R* denatures and more R is converted to R*. A combination of ligand and large 
lipid-detergent micelles can stabilize many GPCRs, but the resultant species are so large 
that the occluded hydrophilic surfaces effectively prevent crystallization. This problem has 
been addressed by binding a Fab antibody fragment to the intracellular part of the receptor, 
dramatically increasing the potential surfaces for making crystal contacts. The strategy was 
used to determine the structure of the β2-adrenergic receptor (β2AR) at 3.4 Å resolution4 (Fig. 
2a). Despite this breakthrough, the resolution of the crystals was insufficient to model side-
chains accurately or to delineate the bound inverse agonist, carazolol.  
A second strategy for increasing the hydrophilic surface is to engineer fusions with T4 
lysozyme (Fig. 2a). Insertion of this protein in the third intracellular loop of β2AR gave better 
crystals that diffracted to higher resolution1, 5 compared with Fab fragment co-crystallization. In 
this case, however, crystals could not be obtained by vapor diffusion and were instead 
formed in lipid cubic phase58. As the major constituent of lipid cubic phase is the single-chain 
lipid mono-olein, which is denaturing, the key to crystallizing the β2AR-T4 lysozyme fusion 
was to add cholesteryl hemisuccinate, which dramatically improved the stability of the 
receptor. In fact, cholesteryl hemisuccinate had long been known to stabilize GPCRs 
solublilized in dodecylmaltoside and is essential for purifying the neurotensin and adenosine 
A2A receptors in functional form27, 59. As cholesteryl hemisuccinate dramatically increases the 
size of the dodecylmaltoside micelle, no crystals have yet been grown by vapor diffusion 
from GPCRs purified in dodecylmaltoside / cholesteryl hemisuccinate . Presumably in lipid 
cubic phase, excess detergent and cholesteryl hemisuccinate diffuses into the mono-olein, 
allowing crystallization to occur. This T4 lysozyme strategy has also been successfully 
applied in the crystallization and structure determination of the adenosine A2A receptor 60.  
A third strategy, which does not rely on fusion proteins or binding partners, is based on 
the observation that short-chain detergents form small micelles around membrane proteins. 
Compared with micelles generated with longer-chain detergents, these micelles leave larger 
hydrophilic areas exposed to form crystal contacts, as can be inferred from the systematic 
size comparisons of detergent micelles containing the mitochondrial ADP/ATP carrier61 (Fig. 
2b). However, short-chain detergents are far more denaturing than the long-chain detergents 
normally used to purify GPCRs in functional form55. Therefore, their use generally requires 
protein thermostabilization. Because bacterial proteins can be thermostabilized by single 
point mutations62, 63, a strategy was developed in which GPCRs were systematically mutated 
by alanine scanning and each mutant tested for thermostability using a radioligand binding 
assay coupled to a heating step64-67. The thermostabilizing point mutations were then 
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combined to make an optimally stable mutant containing 4–6 point mutations. Using this 
approach it was possible to stabilize GPCRs in both agonist- and antagonist-binding 
conformations that were also more stable in short-chain detergents, allowing the structure of 
the thermostabilized β1AR-m23 to be determined to 2.7 Å resolution upon crystallization in 
octylthioglucoside68 (Fig. 2a).  
The introduction of mutations, deletions or insertions to obtain crystals inevitably alters 
a protein’s characteristics and may affect conformational dynamics and ligand affinities. 
Wherever possible, retention of native functionality must be monitored, for example, with 
binding studies65. Clearly, this issue must be carefully considered when using structures of 
engineered proteins to draw conclusions about function. For the β1 and β2 AR structures 
determined to date1, 69-71, it is gratifying that they are all consistent with one another with 
respect to the ligand-binding pocket and that they explain a wealth of earlier biochemical and 
pharmacological data. The presence of T4 lysozyme in the β2 AR fusion does perturb the 
structure of cytoplasmic loops 2 and 3, limiting the utility of the structure for understanding 
the binding of intracellular effectors. However, the fusion strategy has been successfully 
applied to other GPCRs, such as the CXCR4 chemokine receptor72 and the dopamine D3 
receptor73. Much more work is clearly required to understand how membrane proteins like 
GPCRs function in the cell, and any method for increasing the probability of obtaining 
crystals is therefore valuable. 
 
Increasing success rates of crystal optimization and structure solution 
Whether or not a membrane protein has been engineered, its structure after detergent 
solubilization and crystallization (or in the conditions required for nuclear magnetic resonance 
studies) may diverge from its native structure. Unfortunately, there are very few cases in 
which high-resolution structures have been solved by more than one technique, but for 
bacteriorhodopsin74 and AQP075 (electron and X-ray crystallography) and for sensory 
rhodopsin76 (NMR and X-ray crystallography), no large differences in the structural folds were 
observed. However, a lipidic environment can facilitate conformational changes, as 
demonstrated for the transport cycle of bacteriorhodopsin74, 77 and the voltage sensors of the 
voltage-dependent potassium channel78. Thus, it is likely that lipids will be increasingly used 
in future crystallization trials, whether as sponge phase, lipid cubic phase or detergent-lipid 
micelles. 
Crystallization robot technologies, which can dispense nanoliter-scale drops in 96-well 
plates, have substantially increased the number of crystallization conditions that can be 
explored with limited amounts of sample. Robotics is also having an enormous impact on the 
collection of X-ray diffraction data because sample-exchange robots allow crystals to be 
replaced without the need to enter the experimental hutch. In combination with rapid crystal 
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alignment tools, these recent technical advances have increased the number of protein 
crystals screened at the European Synchrotron Radiation Facility by more than an order of 
magnitude in less than a decade79. More crystals being screened for diffraction translates 
into collection of higher-quality X-ray diffraction data, accelerating the rate of progress.  
Another recent innovation at synchrotrons is micro-focus beamlines79. Smaller X-ray 
beams allow useful diffraction data to be extracted from smaller crystals, reducing the time 
required for crystal optimization. Although tighter focus comes at the cost of greater radiation 
damage to the crystal, this problem can be solved by merging data from several crystals, as 
was done for the structure of a human β2AR4. Microfocus beams also make it possible to 
examine the diffraction quality at different regions of the same crystal, allowing data to be 
collected from the best-diffracting regions79. High-quality electron density maps to 1.5 Å 
resolution have been recovered from crystals of the soluble protein xylanase II using a 
microfocus beam of 1 µm2 without any significant radiation damage80. The combination of 
microfocus X-ray beams with rapid-readout pixel- based detectors81 reduces background 
further using ‘fine slicing’ (very small oscillations between each frame) methods of data 
collection, improving the resolution of data that can be extracted from a crystal. This push 
toward increasingly focused X-ray beams will continue as data are recorded from sub-micron 
scale crystals at emerging X-ray-free electron sources; the short X-ray pulse characteristics 
(~100 fs) of this source should enable the traditional radiation barrier of structural biology to 
be superseded82. 
As the database of membrane protein structures has grown, the use of molecular 
replacement for phasing is increasing (Fig. 1b). The combination of molecular replacement 
and co-crystallization with antibody fragments83, 84 or large insertions of known structure1, 5 
(Fig. 2a) is also very powerful, since these additions can aid phasing by molecular 
replacement. Nevertheless, a recent series of very similar structures from transporters with 
no significant sequence homology9-17 highlights the continued importance of experimental 
phasing methods (Fig. 1b). A useful innovation in this respect is the development of a 
convenient method for identifying heavy-atom derivatives covalently bound to cysteine 
residues of solubilized membrane proteins85. In combination with cysteine mutation scanning, 
this approach can facilitate reliable incorporation of heavy atoms for phasing before 
crystallization. Labeling phospholipids specifically with heavy-atom derivatives was 
successful for identifying lipid binding sites but lacked sufficient order to facilitate phasing86.  
Because membrane protein crystals frequently diffract to lower resolution than do 
soluble proteins, innovations that enable structures to be built and refined more reliably at 
low to medium resolution could have a strong impact on the field. A recently proposed 
approach to structural refinement that exploits higher-resolution structural information from 
homologous structures but allows global and local deformations87 may enable membrane 
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protein structures to be refined in the grey zone around 4 Å resolution. Although it is too early 
to judge the impact of this approach on the field, more conservative approaches, such as 
applying H-bond restraints in transmembrane helices, can certainly improve the results of 
structural refinement, as was demonstrated for the sodium-hydantoin transporter, Mhp114, 17. 
New X-ray diffraction and scattering methods are also emerging that move beyond the 
study of a static resting conformation and observe conformational changes within membrane 
proteins in real time at room temperature. Time-resolved Laue diffraction has been used to 
observe light-induced electron density changes in a photosynthetic reaction centre88, and 
time-resolved wide-angle X-ray scattering has provided low-resolution overviews of light-
induced helical movements with time in bacteriorhodopsin and proteorhodopsin89. Although 
Laue diffraction will always be limited by the need to probe reversible reactions in highly 
ordered and robust crystals, time-resolved wide-angle X-ray scattering could develop into a 
generic technique for visualizing the time-scales and nature of global conformational 
changes in membrane proteins.   
 
Conclusion 
Membrane protein families are defined by similarities in their amino acid sequences, 
yet individual proteins in a family can behave very differently with regard to production, 
stability, crystallization and other biophysical and biochemical properties. Conversely, 
proteins unrelated by amino acid sequence may have very similar crystal structures15, 16. 
Several new technologies have recently emerged to help identify and control the biological 
pathways underpinning recombinant membrane protein production, to understand why 
membrane proteins become inactivated upon detergent solubilization and to identify the 
critical parameters in obtaining high-resolution diffraction data. In combination, these diverse 
approaches provide a technical platform for overcoming the major bottlenecks in membrane 
protein structural biology. This potential to build on recent successes is creating an 
atmosphere of confidence that is contagious, triggering a growth in the number of scientists 
forming collaborations, like ours, committed to addressing the major challenges in membrane 
protein structural biology.  
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Figure 1. Progress in solving prokaryotic and eukaryotic membrane protein structures. 
(a) Trends in the use of host cells for the production of recombinant membrane proteins used 
in structural studies. The number of unique α-helical integral membrane protein structures 
deposited each year since 1985 is broken down according to whether the structure was 
derived from natural (black) or recombinant (orange) sources. Inset: a pie chart showing the 
breakdown of various recombinant host sources. (b) Trends in phasing methods for new 
membrane protein structures. The number of unique structures solved using either 
experimental (black) or molecular replacement (orange) methods is shown. Inset: a pie chart 
showing the breakdown of various experimental phasing methods. Unique structures are 
defined according to http://blanco.biomol.uci.edu/Membrane_Proteins_xtal.html. 
 
Figure 2. Strategies for crystallizing membrane proteins (a) Structures of β-AR achieved 
using different approaches:  β2AR engineered with T4 lysozyme inserted into intracellular 
loop 3 was crystallized in lipid cubic phase with cholesteryl hemisuccinate added to stabilize 
the receptor (left); the structure of thermostabilized β1AR-m23 purified in octythioglucoside 
was determined by vapor diffusion crystallization (center);  β2AR stabilized in bicelles and 
bound to a Fab antibody fragment was crystallized by vapor diffusion (right)55. The receptors 
are shown in rainbow coloration, and T4 lysozyme and Fab antibody fragment are shown in 
grey. (b) The relative sizes of the detergent micelles surrounding a small membrane protein. 
The mitochondrial ATP/ADP carrier (30 kDa) was purified in detergents of the alkyl-maltoside 
series with decreasing hydrocarbon chain length from tridecylmaltoside (purple) to 
octylmaltoside (red). The dimensions of the detergent micelles were inferred from the Stokes 
radii of the free and protein-detergent micelles determined by size exclusion 
chromatography90.  
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